Enhancement of anti-tumour immunity in syngeneic mice after MHC class II gene transfection

C. Mongini, Mariano Sanchez-Lockhart, C. I. Waldner, E. M.C. Alvarez, M. J. Gravisaco, M. I. Roig, S. E. Hajos

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The relationship between tumorigenicity and expression of MHC class II molecules in a class II-negative murine leukaemia cell line (LBC) was studied. Analysis of structural DNA sequences encoding MHC class II proteins was performed by Southern blot with DNA isolated from both the original LB tumour and LBC cell line, digested with EcoRI, BamHI and HindIII and hybridised with specific probes for I-Aα(d) and I-Aβ(d) chains. Similar patterns were obtained for LB, LBC and normal BALB/c lymphocytes. In vitro treatment with IFN-γ (20-1000 IU ml-1) failed to induce the expression of MHC class II antigens in LBC cell line. LBC cells were tri-transfected by a liposome-mediated protocol with I-Aα(d), I-Aβ(d) genes and pSVneo. Cells were selected for growth in medium containing Geneticin (G418). Surviving transfectants were cloned and three I-A+ clones were obtained after 20 days (LBCT cells). Syngeneic mice inoculated with 1.0 x 103 LBCT (I-A+) cells failed to develop a tumour, whereas the DT50 of mice injected with 1.0 x 106 LBCT cells was three times the value for mice injected with LBC cells (I-A-). Furthermore, specific CTL response against tumour cells was significantly enhanced upon priming with irradiated LBC-transfected cells (27 ± 2%) compared with irradiated LBC cells (15 ± 1.5%) in a 4 h 51Cr-release assay. It is suggested that neoexpression of MHC class II molecules enhances anti-tumour response by transforming tumour cells into professional antigen-presenting cells (APCs), which may be used to improve tumour-specific immunity in the autologous host.

Original languageEnglish (US)
Pages (from-to)258-263
Number of pages6
JournalBritish journal of cancer
Volume74
Issue number2
DOIs
StatePublished - Jan 1 1996

Fingerprint

MHC Class II Genes
Transfection
Immunity
Neoplasms
Cell Line
Histocompatibility Antigens Class II
Antigen-Presenting Cells
Southern Blotting
Tumor Cell Line
DNA Sequence Analysis
Liposomes
Leukemia
Clone Cells
Lymphocytes

Keywords

  • Anti-tumour immunity
  • Gene transfection
  • Murine leukaemia

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Mongini, C., Sanchez-Lockhart, M., Waldner, C. I., Alvarez, E. M. C., Gravisaco, M. J., Roig, M. I., & Hajos, S. E. (1996). Enhancement of anti-tumour immunity in syngeneic mice after MHC class II gene transfection. British journal of cancer, 74(2), 258-263. https://doi.org/10.1038/bjc.1996.348

Enhancement of anti-tumour immunity in syngeneic mice after MHC class II gene transfection. / Mongini, C.; Sanchez-Lockhart, Mariano; Waldner, C. I.; Alvarez, E. M.C.; Gravisaco, M. J.; Roig, M. I.; Hajos, S. E.

In: British journal of cancer, Vol. 74, No. 2, 01.01.1996, p. 258-263.

Research output: Contribution to journalArticle

Mongini, C, Sanchez-Lockhart, M, Waldner, CI, Alvarez, EMC, Gravisaco, MJ, Roig, MI & Hajos, SE 1996, 'Enhancement of anti-tumour immunity in syngeneic mice after MHC class II gene transfection', British journal of cancer, vol. 74, no. 2, pp. 258-263. https://doi.org/10.1038/bjc.1996.348
Mongini, C. ; Sanchez-Lockhart, Mariano ; Waldner, C. I. ; Alvarez, E. M.C. ; Gravisaco, M. J. ; Roig, M. I. ; Hajos, S. E. / Enhancement of anti-tumour immunity in syngeneic mice after MHC class II gene transfection. In: British journal of cancer. 1996 ; Vol. 74, No. 2. pp. 258-263.
@article{49e876eb600c47afae030bf0f7f71b08,
title = "Enhancement of anti-tumour immunity in syngeneic mice after MHC class II gene transfection",
abstract = "The relationship between tumorigenicity and expression of MHC class II molecules in a class II-negative murine leukaemia cell line (LBC) was studied. Analysis of structural DNA sequences encoding MHC class II proteins was performed by Southern blot with DNA isolated from both the original LB tumour and LBC cell line, digested with EcoRI, BamHI and HindIII and hybridised with specific probes for I-Aα(d) and I-Aβ(d) chains. Similar patterns were obtained for LB, LBC and normal BALB/c lymphocytes. In vitro treatment with IFN-γ (20-1000 IU ml-1) failed to induce the expression of MHC class II antigens in LBC cell line. LBC cells were tri-transfected by a liposome-mediated protocol with I-Aα(d), I-Aβ(d) genes and pSVneo. Cells were selected for growth in medium containing Geneticin (G418). Surviving transfectants were cloned and three I-A+ clones were obtained after 20 days (LBCT cells). Syngeneic mice inoculated with 1.0 x 103 LBCT (I-A+) cells failed to develop a tumour, whereas the DT50 of mice injected with 1.0 x 106 LBCT cells was three times the value for mice injected with LBC cells (I-A-). Furthermore, specific CTL response against tumour cells was significantly enhanced upon priming with irradiated LBC-transfected cells (27 ± 2{\%}) compared with irradiated LBC cells (15 ± 1.5{\%}) in a 4 h 51Cr-release assay. It is suggested that neoexpression of MHC class II molecules enhances anti-tumour response by transforming tumour cells into professional antigen-presenting cells (APCs), which may be used to improve tumour-specific immunity in the autologous host.",
keywords = "Anti-tumour immunity, Gene transfection, Murine leukaemia",
author = "C. Mongini and Mariano Sanchez-Lockhart and Waldner, {C. I.} and Alvarez, {E. M.C.} and Gravisaco, {M. J.} and Roig, {M. I.} and Hajos, {S. E.}",
year = "1996",
month = "1",
day = "1",
doi = "10.1038/bjc.1996.348",
language = "English (US)",
volume = "74",
pages = "258--263",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Enhancement of anti-tumour immunity in syngeneic mice after MHC class II gene transfection

AU - Mongini, C.

AU - Sanchez-Lockhart, Mariano

AU - Waldner, C. I.

AU - Alvarez, E. M.C.

AU - Gravisaco, M. J.

AU - Roig, M. I.

AU - Hajos, S. E.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - The relationship between tumorigenicity and expression of MHC class II molecules in a class II-negative murine leukaemia cell line (LBC) was studied. Analysis of structural DNA sequences encoding MHC class II proteins was performed by Southern blot with DNA isolated from both the original LB tumour and LBC cell line, digested with EcoRI, BamHI and HindIII and hybridised with specific probes for I-Aα(d) and I-Aβ(d) chains. Similar patterns were obtained for LB, LBC and normal BALB/c lymphocytes. In vitro treatment with IFN-γ (20-1000 IU ml-1) failed to induce the expression of MHC class II antigens in LBC cell line. LBC cells were tri-transfected by a liposome-mediated protocol with I-Aα(d), I-Aβ(d) genes and pSVneo. Cells were selected for growth in medium containing Geneticin (G418). Surviving transfectants were cloned and three I-A+ clones were obtained after 20 days (LBCT cells). Syngeneic mice inoculated with 1.0 x 103 LBCT (I-A+) cells failed to develop a tumour, whereas the DT50 of mice injected with 1.0 x 106 LBCT cells was three times the value for mice injected with LBC cells (I-A-). Furthermore, specific CTL response against tumour cells was significantly enhanced upon priming with irradiated LBC-transfected cells (27 ± 2%) compared with irradiated LBC cells (15 ± 1.5%) in a 4 h 51Cr-release assay. It is suggested that neoexpression of MHC class II molecules enhances anti-tumour response by transforming tumour cells into professional antigen-presenting cells (APCs), which may be used to improve tumour-specific immunity in the autologous host.

AB - The relationship between tumorigenicity and expression of MHC class II molecules in a class II-negative murine leukaemia cell line (LBC) was studied. Analysis of structural DNA sequences encoding MHC class II proteins was performed by Southern blot with DNA isolated from both the original LB tumour and LBC cell line, digested with EcoRI, BamHI and HindIII and hybridised with specific probes for I-Aα(d) and I-Aβ(d) chains. Similar patterns were obtained for LB, LBC and normal BALB/c lymphocytes. In vitro treatment with IFN-γ (20-1000 IU ml-1) failed to induce the expression of MHC class II antigens in LBC cell line. LBC cells were tri-transfected by a liposome-mediated protocol with I-Aα(d), I-Aβ(d) genes and pSVneo. Cells were selected for growth in medium containing Geneticin (G418). Surviving transfectants were cloned and three I-A+ clones were obtained after 20 days (LBCT cells). Syngeneic mice inoculated with 1.0 x 103 LBCT (I-A+) cells failed to develop a tumour, whereas the DT50 of mice injected with 1.0 x 106 LBCT cells was three times the value for mice injected with LBC cells (I-A-). Furthermore, specific CTL response against tumour cells was significantly enhanced upon priming with irradiated LBC-transfected cells (27 ± 2%) compared with irradiated LBC cells (15 ± 1.5%) in a 4 h 51Cr-release assay. It is suggested that neoexpression of MHC class II molecules enhances anti-tumour response by transforming tumour cells into professional antigen-presenting cells (APCs), which may be used to improve tumour-specific immunity in the autologous host.

KW - Anti-tumour immunity

KW - Gene transfection

KW - Murine leukaemia

UR - http://www.scopus.com/inward/record.url?scp=0030055507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030055507&partnerID=8YFLogxK

U2 - 10.1038/bjc.1996.348

DO - 10.1038/bjc.1996.348

M3 - Article

VL - 74

SP - 258

EP - 263

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 2

ER -